Drug Trial Radar · NCT03566017
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
Last checked: Nov 20, 2026Latest source record: Mar 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
97
Actual
Start
Sep 16, 2018
Primary completion
Jan 21, 2025
Study completion Jan 21, 2025
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Jun 21, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of CLI-06657AA1-04 (formerly PB-102-F60) was to evaluate the long-term safety, tolerability, and efficacy parameters of 1 mg/kg pegunigalsidase alfa administered intravenously every other week in adult Fabry patients who had successfully completed studies PB-102-F20, PB-102-F30, or at least 48 months in study PB-102-F03.
Conditions
- Fabry Disease
Interventions
pegunigalsidase alfaDrug
Recombinant human alpha galactosidase A
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-related Adverse EventsTime frame: From first ever infusion of pegunigalsidase alfa, which could have been in the parent study (PB-102-F01/F20/F30) or this extension study, CLI-06657AA1-04, until 90 days after the final dose visit for each participant. Mean individual exposure: 5.5 years
Locations
30 sites in 13 countries. Site status is shown where the registry gives one.
UAB Medicine
Birmingham, Alabama
Phoenix Children's Hospital
Phoenix, Arizona
University of California San Diego
La Jolla, California
University of California Irvine Center
Orange, California
University of Florida
Gainesville, Florida
Emory University School of Medicine
Atlanta, Georgia
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Infusion Associates
Grand Rapids, Michigan
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
University of Pittsburgh
Pittsburgh, Pennsylvania
Renal Disease Research Institute, LLC - Dallas
Dallas, Texas
Institute of Metabolic Disease
Dallas, Texas
University of Utah Hospitals & Clinics
Salt Lake City, Utah
O+O Alpan LLC
Fairfax, Virginia
Medical College of Wisconsin
Milwaukee, Wisconsin
Royal Melbourne Hospital
Parkville, Victoria, Australia
Capital District Health Authority
Halifax, Nova Scotia, Canada
Vseobecna fakultni nemocnice v Praze
Prague, Czech Republic, Czechia
Turku University Central Hospital
Turku, Finland
Hospital Raymond-Poincaré
Garches, France
Semmelweis Egyetem
Budapest, Hungary
Azienda Ospedaliera Universitaria "Federico II"
Naples, Via Pansini, Italy
Academisch Medisch Centrum
Amsterdam, Netherlands
Haukeland University Hospital Klinisk Forskningspost
Bergen, Norway
General Hospital Slovenj Gradec
Slovenj Gradec, Slovenia
Hospital de Dia Quiron Zaragoza
Zaragoza, Spain
Addenbrooke's Hospital
Cambridge, United Kingdom
The Royal Free Hospital
London, United Kingdom
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital
Edgbaston, Birmingham, United Kingdom
Salford Royal
Salford, Greater Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.